Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJohn MosiorJWJin Wang

Discussion

Loading...

Member takes

Overview

Observational analysis showed that menin inhibitors reduced cell growth in AML, indicating differentiation is reversible without resistance.

Key Points

  • Reversible differentiation in AML leads to resumed cell growth after menin inhibitor withdrawal.
  • The study found that CD11b expression significantly decreases after treatment cessation, tracking differentiation.
  • Analysis of regrown cells revealed no difference in IC50, confirming the reversibility of menin inhibitors.
  • Chromatin modulation enhances differentiation stabilization and increases accessibility in lineage-specific genes.

Cite This Study

Mosior et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d602https://doi.org/10.1182/blood-2025-3295
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors2025
  2. 2Post allo-HCT menin-inhibition enhances graft-versus-leukemia effects by endogenous retrovirus induction in AML and T-cell activation2025
  3. 3Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms2025
  4. 4Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia2025 · 1 citations
  5. 5Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models2025 · 1 citations